EMAN RESEARCH PUBLISHING | Journal | Just Accepted Abstract
CASE STUDY   (Open Access)

Clinical Significance of Personalized Neoantigen Vaccine (G1-PES) for The Treatment of Various Types of Advanced Metastatic Cancer Patients in 2001 to 2014: Treatment Case Reports

John A Catanazaro1*, Md Shamsuddin Sultan Khan 1, Mohamed Khadeer Ahmded Basheer 2, Anton Yuryev 1, Andrew Dickens 1

+ Author Affiliations

Journal of Precision Biosciences 2(1) 106-115 https://doi.org/10.25163/biosciences.21210160506070820

Submitted: 05 July 2020  Revised: 05 August 2020  Published: 07 August 2020 

Neoantigen cancer vaccine is highly effective to treat the various types of cancer which is conducted in 2001 to 2014 at Health and Wellness Institute Integrative Cancer Treatment under the direction of Dr. Catanzaro and his team of physicians. 

Abstract

Immunopeptide therapy has provided significant clinical improvements in the treatment of several malignancies. The generation 1 personalized edited sequence (G1-PES) vaccine administered to 43 severe metastatic cancer patients (terminal stage), safely and effectively in Dr. Catanzaro’s clinic in 2001 to 2014. These all patients were considered for 3 to 4 months life support with no hope. Patients were on G1-PES an 18-month therapy program with the objective of achieving remission and cancer free survival within 18 months. Typically, patients received 4 cycles every 12 weeks. The safety and efficacy were assessed through adverse events, progression-free survival (PFS), overall survival (OS) and other parameters. Patients that received G1-PES were free from any serious adverse effects (SAE’s), while receiving and after therapy.  Typical reactions included slight fever, flu-like symptoms for 1-2 days and rash at route of administration site that lasted for 2-3 days.  All of these minor reactions were self-limiting.  Patients had significantly improved quality of life within 1-3 weeks of receiving therapy, with diminishing symptoms associated with their cancer and clinical evidence of cancer regression (p<0.001). G1-PES vaccine was feasible and safe for patients with advanced metastatic cancer. G1-PES vaccine was designed based on T cell-mediated immune response targeting tumor neoantigens as antitumor efficacy.

Key words: Immunotherapy, Cancer, G1-PES (Generation-1 Personalized Edited Sequence), Neoantigen, Personalized vaccine, Peptide vaccine, Advanced malignant tumor

References

Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A. and Jemal A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68, 394-424.
https://doi.org/10.3322/caac.21492
PMid:30207593
 
Carreno, B. M. et al. (2015). A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348, 803-808.
https://doi.org/10.1126/science.aaa3828
PMid:25837513 PMCid:PMC4549796
 
Chen F., Wei J. and Liu B. (2019). Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. J Clin Invest, 129(5):2056-2070.
https://doi.org/10.1172/JCI99538
PMid:30835255 PMCid:PMC6486339
 
Guo Y., Lei K., and Tang L. (2018). Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy. Front Immunol, 9, 1499. doi:10.3389/fimmu.2018.01499.
https://doi.org/10.3389/fimmu.2018.01499
PMid:30013560 PMCid:PMC6036114
 
Khong, H. and Overwijk, W.W. (2016). Adjuvants for peptide-based cancer vaccines. Journal for Immunotherapy of Cancer, 4(56). doi:10.1186/s40425-016-0160-y.
https://doi.org/10.1186/s40425-016-0160-y
PMid:27660710 PMCid:PMC5028954
 
Linnemann, C. et al. (2015). High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat. Med. 21, 81-85.
https://doi.org/10.1038/nm.3773
PMid:25531942
 
McGahan JP, Brock JM, Tesluk H, Gu WZ, Schneider P, Browning PD. (1992). Hepatic ablation with use of radio-frequency electrocautery in the animal model. J Vasc Interv Radiol, 3(2), 291-7. doi 10.1016/s1051-0443(92)72028-4.
https://doi.org/10.1016/S1051-0443(92)72028-4
 
Ott P. A., Hu Z., Keskin D. B., Shukla S. A., Sun J., Bozym D. J., Zhang W., Luoma A., Giobbie-Hurder A., Peter L., Chen C., Olive O., Carter T. A., Li S., Lieb D. J., Eisenhaure T., Gjini E., Stevens J., Lane W. J., Javeri, I. and Wu, C. J. (2017). An immunogenic personal neoantigen vaccine for patients with melanoma. Nature, 547(7662), 217-221.
https://doi.org/10.1038/nature22991
PMid:28678778 PMCid:PMC5577644
 
Peng M., Mo Y., Wang Y., Wu P., Zhang Y., Xiong F., Guo C., Wu,X., Li Y., Li X., Li G., Xiong W. and Zeng Z. (2019). Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer, 18, 128.
https://doi.org/10.1186/s12943-019-1055-6
PMid:31443694 PMCid:PMC6708248
 
Prickett, T. D. et al. (2016). Durable complete response from metastatic melanoma after transfer of autologous T cells recognizing 10 mutated tumor antigens. Cancer Immunol. Res. 4, 669-678.
https://doi.org/10.1158/2326-6066.CIR-15-0215
PMid:27312342 PMCid:PMC4970903
 
Rizvi, N. A. et al. (2015). Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128.
https://doi.org/10.1126/science.aaa1348
PMid:25765070 PMCid:PMC4993154
 
Schumacher, T. et al. (2014). A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512, 324-327.
https://doi.org/10.1038/nature13387
PMid:25043048
 
Tran, E. et al. (2014). Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641-645 (2014)
https://doi.org/10.1126/science.1251102
PMid:24812403 PMCid:PMC6686185
 
Van Rooij, N. et al. (2013). Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31, e439-e442.
https://doi.org/10.1200/JCO.2012.47.7521
PMid:24043743 PMCid:PMC3836220
 
Wang S., Liu H., Zhang X. and Qian F. (2015). Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies. Protein Cell, 6(7), 480-503.
https://doi.org/10.1007/s13238-015-0164-2
PMid:25944045 PMCid:PMC4491048
 
Widenmeyer M, Shebzukhov Y, Haen SP, Schmidt D, Clasen S, Boss A, et al. (2011). Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation. Int J Cancer, 128(11), 2653-62 doi 10.1002/ijc.25601.
https://doi.org/10.1002/ijc.25601
PMid:20715115
 
Yarchoan M., Johnson B.A., Lutz E.R., Laheru D.A. and Jaffee E.M. (2017). Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer, 17, 209-22. 10.1038/nrc.2016.154.
https://doi.org/10.1038/nrc.2017.74
https://doi.org/10.1038/nrc.2016.154
PMid:28233802 PMCid:PMC5575801
 
Yoshida K, Noguchi M, Mine T, Komatsu N., Yutani S., Ueno T., Yanagimoto H., Kawano K., Itoh K., and Yamada A. (2011). Characteristics of severe adverse events after peptide vaccination for advanced cancer patients: Analysis of 500 cases. Oncol Rep, 25(1):57-62.
https://doi.org/10.3892/or_00001041
PMid:21152877
 
Yuryev A. and Catanzaro J. (2019). Development of Personalized Therapeutics Using Neo7logix® Precision Profiling for Progressive CNS Inflammation and Autoimmune Disease. Biosciences, 1(1), 001-006.
https://doi.org/10.25163/biosciences.112087DB112921119
https://doi.org/10.25163/biosciences.112090DB112921119
 
Yuryev A., Catanzaro J., Khan, M. S. S. (2019a). Development of Personalized Therapeutics Using Neo7logix Precision Profiling in Lung Cancer. Biosciences, 1(1), 016-025.
https://doi.org/10.25163/biosciences.112090DB112921119

Committee on Publication Ethics

PDF
Full Text
Export Citation

View Dimensions


View Plumx



View Altmetric



0
Save
0
Citation
657
View
0
Share